Twitter LinkedIn
    Saturday, April 1
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Funds»China’s HLC, Panacea lead $100m funding in biotech startup Inmagene
    Funds

    China’s HLC, Panacea lead $100m funding in biotech startup Inmagene

    June 1, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Inmagene Biopharmaceuticals, a biotech startup with offices in China and the US, has closed $100 million in a Series C round of financing jointly led by health-focused HighLight Capital (HLC) and Panacea Venture, the startup announced in a WeChat post on Tuesday.

    The Series C round provided Inmagene – which is developing a pipeline of nearly 20 drug candidates for immunological diseases – with new proceeds to fund its scientific research, drug innovation, clinical development, product introduction, and the construction of new manufacturing facilities.

    With the new financing, Inmagene has secured about $140 million across three rounds since its inception in 2019. In November 2020, the startup announced the completion of a $21-million Series B round led by Vertex Ventures China, a China-focused affiliate of Singapore-based venture capital (VC) firm Vertex Ventures.

    It completed a $20-million Series A round in September 2019, according to Chinese third-party business data platform Tianyancha. Investors of the initial round were not disclosed.

    Biotech startups in the Greater China region collectively raised at least $710 million across 18 investments in April 2021, putting the sector as one of the top three most popular areas for investors to make bets, according to proprietary data from DealStreetAsia’s China Deal Review.

    Read more/Source: 24h Tech Asia

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    BiotechChina peinsider Private Equity Venture Capital
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    KKR looking to sell Canadian gas producer Westbrick for $1.13B

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Comments are closed.

    Other Articles

    Albion Capital launches GBP45m VCT fundraising

    January 9, 2021

    Canada’s CPPIB names Suyi Kim as global PE boss

    July 29, 2021

    H.I.G. Capital Enters Into Agreement to Sell Valtris Specialty Chemicals

    May 12, 2022

    GIC and Oak Street to acquire STORE Capital in $14B deal

    September 16, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?